ATE494381T1 - Verbesserte expressionselemente - Google Patents

Verbesserte expressionselemente

Info

Publication number
ATE494381T1
ATE494381T1 AT06727026T AT06727026T ATE494381T1 AT E494381 T1 ATE494381 T1 AT E494381T1 AT 06727026 T AT06727026 T AT 06727026T AT 06727026 T AT06727026 T AT 06727026T AT E494381 T1 ATE494381 T1 AT E494381T1
Authority
AT
Austria
Prior art keywords
genetic elements
expression elements
improved expression
levels
expression
Prior art date
Application number
AT06727026T
Other languages
English (en)
Inventor
David John Simpson
Steven Geraint Williams
Alistair Simpson Irvine
Original Assignee
Millipore Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millipore Corp filed Critical Millipore Corp
Application granted granted Critical
Publication of ATE494381T1 publication Critical patent/ATE494381T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT06727026T 2005-05-17 2006-05-09 Verbesserte expressionselemente ATE494381T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0509965.0A GB0509965D0 (en) 2005-05-17 2005-05-17 Improved expression elements
US68227705P 2005-05-18 2005-05-18
PCT/GB2006/001656 WO2006123097A2 (en) 2005-05-17 2006-05-09 Improved expression elements

Publications (1)

Publication Number Publication Date
ATE494381T1 true ATE494381T1 (de) 2011-01-15

Family

ID=34708242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06727026T ATE494381T1 (de) 2005-05-17 2006-05-09 Verbesserte expressionselemente

Country Status (9)

Country Link
US (2) US7632661B2 (de)
EP (2) EP1891223B1 (de)
JP (1) JP5080452B2 (de)
CN (1) CN101208435B (de)
AT (1) ATE494381T1 (de)
DE (1) DE602006019422D1 (de)
ES (1) ES2358680T3 (de)
GB (1) GB0509965D0 (de)
WO (1) WO2006123097A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036449T2 (hu) 2003-06-24 2018-07-30 Genzyme Corp Új béta-aktin és RPS21 promóterek és alkalmazásaik
JP2010505442A (ja) * 2006-10-10 2010-02-25 ビロメッド カンパニー， リミテッド 安全性の改善された発現ベクター
JP2010515435A (ja) * 2007-01-08 2010-05-13 ミリポア・コーポレイション 遺伝子増幅を不要とする高発現細胞株
WO2009155950A1 (en) * 2008-06-27 2009-12-30 King Faisal Specialist Hospital And Research Centre Cloning-free method of generating transcriptionally and post-transcriptionally controllable expression active linear reporter constructs
US20110190156A1 (en) * 2008-07-15 2011-08-04 Trustees Of Dartmouth College Molecular signatures for diagnosing scleroderma
JP2012522013A (ja) * 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
EP2443239B1 (de) 2009-06-15 2015-11-25 Cellagenics B.V. Neue stringent selektionsmarker
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
DK2611915T3 (da) 2010-09-01 2015-06-22 Cellagenics B V Nukleinsyrefragmenter fra en ribosomal proteinpromoter til forstærkning af genekspression
TW201632624A (zh) 2011-11-28 2016-09-16 第一三共股份有限公司 源自人類基因的啟動子
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
MX362981B (es) 2012-03-27 2019-02-28 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
WO2013163404A1 (en) * 2012-04-27 2013-10-31 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
EP3842537A1 (de) * 2013-12-30 2021-06-30 CureVac AG Künstliche nukleinsäuremoleküle
CN111304231A (zh) 2013-12-30 2020-06-19 库瑞瓦格股份公司 人工核酸分子
MX377591B (es) * 2014-10-15 2025-03-10 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas.
CA2995248A1 (en) * 2015-09-02 2017-03-09 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
WO2018206168A1 (en) * 2017-05-11 2018-11-15 Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh Concept for the treatment of monogenetic disorders
CA3109101A1 (en) 2018-08-09 2020-02-13 Daiichi Sankyo Company, Limited Promoter of hspa8 gene
WO2020223160A1 (en) 2019-04-30 2020-11-05 Chan Zuckerberg Biohub, Inc. A novel chromatin-opening element for stable long term gene expression
CN111249457A (zh) * 2020-04-13 2020-06-09 吉林大学 核糖体蛋白sa抗体在免疫调节中的医用用途
WO2023210607A1 (ja) 2022-04-26 2023-11-02 第一三共株式会社 Ｅｎｏ１遺伝子のプロモーター
CN116064624A (zh) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 利用rpl基因促进载体稳定表达的方法及其功能基因
CN116064663A (zh) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 利用rps基因促进载体稳定表达的方法及其功能基因

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583009A (en) * 1992-12-08 1996-12-10 University Of Washington Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression
US5610053A (en) * 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US6110666A (en) 1994-06-09 2000-08-29 Medical Research Council Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
JP2000516472A (ja) 1996-08-16 2000-12-12 メディカル リサーチ カウンシル 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター
ATE539161T1 (de) * 1998-07-21 2012-01-15 Millipore Corp Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid
AU771111B2 (en) * 1998-07-21 2004-03-11 Emd Millipore Corporation A polynucleotide comprising a ubiquitous chromatin opening element (UCOE)
GB0022995D0 (en) * 2000-09-20 2000-11-01 Cobra Therapeutics Ltd Polynucleotide
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
JP2005500019A (ja) * 2001-04-05 2005-01-06 エムエル ラボラトリーズ ピーエルシー 改良された遺伝子発現
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
KR20040032105A (ko) * 2001-06-04 2004-04-14 엠엘 래보러토리즈 피엘씨 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
CN1526011A (zh) 2001-07-10 2004-09-01 IDECҩ�﹫˾ 抑制凋亡过程及改善细胞性能
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products

Also Published As

Publication number Publication date
US7632661B2 (en) 2009-12-15
EP1891223B1 (de) 2011-01-05
EP1891223A2 (de) 2008-02-27
US20100015107A1 (en) 2010-01-21
US20080097088A1 (en) 2008-04-24
JP5080452B2 (ja) 2012-11-21
WO2006123097A3 (en) 2007-01-11
DE602006019422D1 (de) 2011-02-17
CN101208435B (zh) 2012-05-23
ES2358680T3 (es) 2011-05-12
GB0509965D0 (en) 2005-06-22
JP2008539781A (ja) 2008-11-20
CN101208435A (zh) 2008-06-25
WO2006123097A2 (en) 2006-11-23
EP2295589A1 (de) 2011-03-16

Similar Documents

Publication Publication Date Title
ATE494381T1 (de) Verbesserte expressionselemente
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
WO2003080807A8 (en) Compositions and methods for suppressing eukaryotic gene expression
AR059257A1 (es) Genes para mejorar la eficiencia de la utilizacion de nitrogeno en los cultivos
EP2037892A4 (de) Modifizierte fatkor-viii- und faktor-ix-gene und vektoren für gentherapie
TW200602491A (en) Human GLP-1 mimetibodies, compositions, methods and uses
WO2008122811A3 (en) Adenoviral vectors encoding a pathogen or tumour antigen
PH12013502425B1 (en) Smoothened polypeptides and methods of use
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
AR072695A2 (es) Proteinas insecticidas de bacillus thuringiensis
ATE386127T1 (de) Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
EA201270574A1 (ru) Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
MX2022011806A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
AU2004269200A8 (en) Enhancing accumulation of heterologous polypeptides in plant seeds through targeted suppression of endogenous storage proteins
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
AR049224A1 (es) Composiciones y metodos para la modificacion de la expresion genica
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2007127347A3 (en) An isolated dna fragment of the sparc human promoter and its use
WO2006033668A3 (en) Pcka modifications and enhanced protein expression in bacillus
DK1673391T3 (da) Modificeret cDNA til höje ekspressionsniveauer af faktor VIII og dens derivater
AR053284A1 (es) Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada
ATE471988T1 (de) Verbesserte genetische elemente für eine erhöhte genexpression
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
陈礼刚 et al. Protective Effects of Intracord Transplantation of pSVPoMcat Modified Schwann Cells on Spinal Cord Injury

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties